Indian Journal of Rheumatology

REVIEW ARTICLE
Year
: 2012  |  Volume : 7  |  Issue : 2  |  Page : 83--88

Methotrexate induced pneumonitis


S Nagaraj, Piyush Joshi, Vinay Ramachandra Joshi 
 PD Hinduja National Hospital and Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai 400016, India

Correspondence Address:
Vinay Ramachandra Joshi
PD Hinduja National Hospital and Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai 400016
India

Methotrexate induced pneumonitis (MTX-P) is an uncommon, but potentially serious and life-threatening adverse event. The dose, duration of treatment and route of administration of methotrexate bear no relationship to MTX-P. Many risk factors have been studied but no definitive risk factor is identified. Pre-existing pulmonary disease may be associated with increased risk of MTX-P. Several sets of criteria have been proposed for diagnosis of MTX-P but none are validated. Diagnosis is mainly clinical and requires a high degree of suspicion. Treatment is mainly supportive along with discontinuation of methotrexate. Most patients recover. Mortality up to 17% has been reported in literature. Reintroduction of methotrexate after recovering from MTX-P is generally avoided. This article focuses on the epidemiology, clinical presentation, pathology, laboratory features and management of MTX-P.


How to cite this article:
Nagaraj S, Joshi P, Joshi VR. Methotrexate induced pneumonitis .Indian J Rheumatol 2012;7:83-88


How to cite this URL:
Nagaraj S, Joshi P, Joshi VR. Methotrexate induced pneumonitis . Indian J Rheumatol [serial online] 2012 [cited 2021 Oct 16 ];7:83-88
Available from: https://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2012;volume=7;issue=2;spage=83;epage=88;aulast=Nagaraj;type=0